Clinical trial
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
NCT00002920
Study timeline
Study start (unknown)1997-03-01Date precision: month
Registry last updated2012-10-31
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Endometrial Cancerunresolved
Interventions
medroxyprogesteroneDRUG · verified · RxNorm: medroxyprogesterone
tamoxifen citrateDRUG · verified · RxNorm: tamoxifen citrate
adjuvant therapyPROCEDURE
Sponsors & collaborators
SWOG Cancer Research Networklead sponsor
National Cancer Institute (NCI)collaborator
Cancer and Leukemia Group Bcollaborator
Mapped research locations
ChicagoIllinois, United States4New YorkNew York, United States3St LouisMissouri, United States3SeattleWashington, United States3PortlandOregon, United States3DetroitMichigan, United States3New OrleansLouisiana, United States3Los AngelesCalifornia, United States2San AntonioTexas, United States2CincinnatiOhio, United States2ColumbusOhio, United States2Washington D.C.District of Columbia, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00002920 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.